Lymphokines, E.g., Interferons, Interlukins, Etc. Patents (Class 530/351)
-
Publication number: 20120115772Abstract: A process for the conjugation of a polymer to a protein, which comprises reacting a polymeric conjugating agent with said protein, in an aqueous medium, in the presence of an amphipathic sugar polymer. The process is particularly useful when conjugating PEG to proteins, particularly to proteins which have previously proved difficult to PEGylate in acceptable yields, for example INF-?.Type: ApplicationFiled: July 15, 2010Publication date: May 10, 2012Inventors: Ji-Won Choi, Antony Godwin, Estera Pawlisz
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120114595Abstract: Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position corresponding to the 69-position of the amino acid sequence of human AILIM extracellular domain, said amino acid sequence being depicted in SEQ ID NO: 7, and no sugar chain is added at positions corresponding to the 3-position and the 90-position of the amino acid sequence.Type: ApplicationFiled: July 12, 2010Publication date: May 10, 2012Applicant: OTSUKA CHEMICAL CO., LTD.Inventors: Yasuhiro Kajihara, Takashi Tsuji, Katsunari Tezuka, Kenta Yoshida, Kazuhiro Fukae
-
Publication number: 20120114602Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.Type: ApplicationFiled: June 4, 2010Publication date: May 10, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'Este, Davide Renier, Gianfranco Pasut, Antonio Rosato
-
Publication number: 20120116054Abstract: The invention provides, among other things, lyophilized compositions of high surface area that comprise a protein and that reconstitute quickly and efficiently to solution of high protein concentration with minimal formation, if any, of foam, effervescence, bubbles, turbidity, or particulates that might be deleterious. The invention also provides, among other things, methods for making the lyophilized compositions. The invention in additional aspects also provides Raman Imaging Spectrographic methods for real time analyses of polymorphs in a sample using PLS algorithms. By way of particular example, the use of the method for the analysis of mannitol polymorphs is described, and the use of the analysis to determine optimum compositions and lyophilization methods for producing lyophilates of pharmaceutical proteins having a predefined distribution of mannitol polymorphs and having the aforementioned reconstitution properties is also described.Type: ApplicationFiled: May 6, 2011Publication date: May 10, 2012Inventors: Sampathkumar Krishnan, Monica Pallitto, Margaret Ricci, Wenjin Cao, Hong Lin, Yong Xie, Samantha Nagle, Shon Lee Crampton
-
Publication number: 20120114603Abstract: A novel IFN-?/? independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-?1, IFN-?2, IFN-?3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-? proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-?R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-?R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection.Type: ApplicationFiled: October 5, 2010Publication date: May 10, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Sergei Kotenko, Grant F. Gallagher
-
Patent number: 8173117Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: July 9, 2010Date of Patent: May 8, 2012Assignee: Schering CorporationInventors: Gerard T. Hardiman, Devora L. Rossi, Kevin B Bacon, Bazan Fernando J., Thomas P. Schall, Albert Zlotnik
-
Publication number: 20120107267Abstract: The invention relates to isolated IL-21 variant peptides having antagonistic binding to the common gamma chain (yC) of the IL-21 receptor, to pharmaceutical compositions comprising said peptides and to the use of said peptides in therapy.Type: ApplicationFiled: March 10, 2010Publication date: May 3, 2012Applicant: Novo Nordisk A/SInventors: Lishan Kang, Kent Bondensgaard, Siv Annegrethe Hjorth
-
Patent number: 8168751Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.Type: GrantFiled: December 21, 2007Date of Patent: May 1, 2012Assignees: Beijing Tri-Prime Genetic Engineering Co., Ltd., Beijing Bio-Tech Development Co., Ltd.Inventors: Jinyi Liu, Xiaoxia Niu, Minyi Zhou, Yi Yang, Jianbo Sun, Yongqing Cheng
-
Patent number: 8168752Abstract: The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.Type: GrantFiled: October 6, 2009Date of Patent: May 1, 2012Assignee: Boehringer Ingelheim Pharmaceutical, Inc.Inventors: Jianfei Yang, Frank James King, Jun Li, Zhenhao Qi, Ming Xue
-
Publication number: 20120100099Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.Type: ApplicationFiled: October 17, 2011Publication date: April 26, 2012Applicant: NOVAGEN HOLDING CORPORATIONInventors: Haitao WANG, Longbin LIU, Rui ZHANG, Jing XU, Yong DU
-
Publication number: 20120100185Abstract: The present invention provides methods and compositions for tissue regeneration without cell transplantation.Type: ApplicationFiled: April 13, 2010Publication date: April 26, 2012Inventors: Xuejun Wen, Yongzhi Qiu, Wendy S. Vanden Berg-Foels
-
Publication number: 20120101254Abstract: Reagents and methods for functionalising polypeptides with moieties poly (alkylene glycol) molecules and glycan groups are disclosed that are based on a functionalising reagent which comprises a nitrogen containing heterocyclic aromatic ring having a vinyl substituent that is capable of reacting with one or more thiol groups that are naturally present, or have been introduced into, the polypeptide, for example by employing a thiol group of one or more cysteine residues. The functionalising reagent is covalently linked to a poly (alkylene glycol) molecule, such as a polyethylene glycol (PEG) molecule, or a glycan group so that the reaction between the vinyl group and the thiol group in the polypeptide covalently links the polypeptide to the poly (alkylene glycol) molecule and/or the glycan group.Type: ApplicationFiled: December 21, 2009Publication date: April 26, 2012Inventors: Andrew Graham Watts, Terrence Kantner, Amanda Barbara MacKenze
-
Publication number: 20120100158Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.Type: ApplicationFiled: April 29, 2010Publication date: April 26, 2012Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Gal Markel, Rona Ortenberg
-
Patent number: 8163879Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: GrantFiled: February 5, 2010Date of Patent: April 24, 2012Assignee: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Publication number: 20120094356Abstract: The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.Type: ApplicationFiled: April 22, 2010Publication date: April 19, 2012Applicant: ALTEOGEN, INC.Inventors: Hye-Shin Chung, Seung Bum Yoo, Sang Mee Lee
-
Publication number: 20120088904Abstract: A method for predicting response of a patient infected with HCV-1a to interferon treatmentType: ApplicationFiled: February 28, 2011Publication date: April 12, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Douglas John Bartels, Ann Dak-Yee Kwong, Tara Lynn Kieffer
-
Patent number: 8153113Abstract: This invention provides a method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue in a subject comprising administering to the subject an amount of interleukin-8 effective to attract endothelial progenitor cells to the ischemia-damaged tissue.Type: GrantFiled: August 20, 2007Date of Patent: April 10, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventor: Silviu Itescu
-
Publication number: 20120083008Abstract: The invention provides a method for reducing immunogenicity of a peptide, protein or protein complex in an individual comprising introducing at least one cross-link between two amino acids in the peptide, protein or protein complex that is stable or irreversible in vivo, wherein the at least one cross-link reduces the immunogenicity of the peptide, protein or protein complex in the individual compared to an identical peptide, protein or protein complex not so cross-linked.Type: ApplicationFiled: June 19, 2009Publication date: April 5, 2012Inventor: Christopher P. Marshall
-
Publication number: 20120082644Abstract: The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.Type: ApplicationFiled: March 31, 2010Publication date: April 5, 2012Inventor: Mark D. Mannie
-
Patent number: 8148109Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.Type: GrantFiled: August 8, 2005Date of Patent: April 3, 2012Assignee: Amgen Inc.Inventors: Andrew Welcher, Duanzhi Wen, Michael Kelley
-
Patent number: 8148500Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: September 21, 2010Date of Patent: April 3, 2012Assignee: Bolder BioTechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 8147844Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.Type: GrantFiled: December 28, 1994Date of Patent: April 3, 2012Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. de Sauvage
-
Patent number: 8147817Abstract: This invention relates to methods and compositions for the treatment and diagnosis of cardiac diseases and disorders, such as cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis and heart failure. The invention also relates to methods and compositions for the treatment of fibrosis-related diseases as well as methods and compositions for reducing apoptosis, increasing ST2L signaling, decreasing NF-?B activation, decreasing I?B? phosphorylation, decreasing P38MAPK phosphorylation, decreasing JNK phosphorylation, decreasing reactive oxygen species generation, decreasing macrophage infiltration and/or decreasing the expression of hypertrophic genes. More specifically, the invention relates to IL-33 and/or soluble ST2 inhibiting agents for use in the methods and compositions provided.Type: GrantFiled: May 4, 2007Date of Patent: April 3, 2012Assignee: The Brigham and Women's Hospital, Inc.Inventor: Richard T. Lee
-
Patent number: 8147843Abstract: The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.Type: GrantFiled: August 28, 2007Date of Patent: April 3, 2012Assignee: Apogenix GmbHInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
-
Publication number: 20120077731Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: April 12, 2010Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20120077228Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.Type: ApplicationFiled: April 28, 2011Publication date: March 29, 2012Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: David A. Tirrell, Kristi Lynn Kiick
-
Patent number: 8143214Abstract: Protein-polymer conjugates are described. Also described are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.Type: GrantFiled: August 15, 2008Date of Patent: March 27, 2012Assignee: PharmaEssentia Corp.Inventor: Ko-Chung Lin
-
Publication number: 20120070406Abstract: The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the compositions having low immunogenic potential and/or improved efficacy. The invention achieves these goals by evaluating therapeutic protein preparations for subvisible protein particulates, which can contribute significantly to the overall immunogenic potential of the protein preparation. Further, by maintaining the content of such subvisible protein particulates to below an immunogenic threshold level, the resulting pharmaceutical composition is less likely to result in a loss of tolerance (e.g., upon repeated administration), thereby improving both the safety and efficacy profile of the therapeutic.Type: ApplicationFiled: July 19, 2011Publication date: March 22, 2012Applicants: The Regents of the University of Colorado, A Body Corporate, Barofold, Inc.Inventors: Matthew SEEFELDT, Theodore W. RANDOLPH, Amber Haynes FRADKIN, John CARPENTER
-
Patent number: 8137671Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: May 5, 2010Date of Patent: March 20, 2012Assignee: Genentech, Inc.Inventors: Krzysztof Masternak, Francois Rousseau
-
Patent number: 8138312Abstract: The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.Type: GrantFiled: June 11, 2009Date of Patent: March 20, 2012Assignee: The Regents of the University of Colorado, a body corporateInventors: Soo-Hyun Kim, Charles A. Dinarello, Tania Azam
-
Publication number: 20120065365Abstract: Stabilized radiopharmaceutical formulations are disclosed. Methods of making and using stabilized radiopharmaceutical formulations are also disclosed. The invention relates to stabilizers that improve the radiostability of radiotherapeutic and radiodiagnostic compounds and formulations containing them. In particular, it relates to stabilizers useful in the preparation and stabilization of targeted radiodiagnostic and radiotherapeutic compounds, and, in a preferred embodiment, to the preparation and stabilization of radiodiagnostic and radiotherapeutic compounds that are targeted to the Gastrin Releasing Peptide Receptor (GRP-Receptor).Type: ApplicationFiled: October 25, 2011Publication date: March 15, 2012Applicant: BRACCO IMAGING S.P.A.Inventors: Jianqing Chen, Karen E. Linder, Edmund R. Marinelli, Edmund Metcalfe, Adrian D. Nunn, Rolf E. Swenson, Michael F. Tweedle
-
Patent number: 8133976Abstract: The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.Type: GrantFiled: November 6, 2009Date of Patent: March 13, 2012Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Wanwan S. Din
-
Publication number: 20120058084Abstract: The present invention relates to a pharmaceutical composition comprising a water-soluble polymeric carrier linked prodrug of interferon alpha, wherein the prodrug is capable of releasing free interferon alpha, wherein the release half life under physiological conditions is at least 4 days. The invention further relates to prodrugs for said pharmaceutical composition and their use for treating, controlling, delaying or preventing a condition that can benefit from interferon alpha treatment, such as hepatitis C.Type: ApplicationFiled: March 4, 2010Publication date: March 8, 2012Applicant: ASCENDIS PHARMA ASInventors: Harald Rau, Silvia Kaden-Vagt
-
Publication number: 20120058083Abstract: The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-? therapeutics.Type: ApplicationFiled: November 11, 2010Publication date: March 8, 2012Applicant: Biogen Idec MA Inc.Inventor: Alfred Sandrock
-
Publication number: 20120052043Abstract: A fusion protein comprising at least one chemokine or a derivative or fragment thereof and at least one peptide derived from a chaperone. The fusion protein can be provided in a pharmaceutical preparation for the treatment of inflammatory conditions or cancer.Type: ApplicationFiled: December 20, 2007Publication date: March 1, 2012Inventor: Andreas Kungl
-
Publication number: 20120052042Abstract: The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.Type: ApplicationFiled: February 22, 2010Publication date: March 1, 2012Inventors: Sébastien Ladet, Philippe Gravagna
-
Patent number: 8124084Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.Type: GrantFiled: May 17, 2006Date of Patent: February 28, 2012Assignee: University of ConnecticutInventors: Leo Lefrancois, Thomas A. Stoklasek
-
Patent number: 8124065Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.Type: GrantFiled: February 15, 2011Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
-
Patent number: 8124099Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.Type: GrantFiled: January 30, 2007Date of Patent: February 28, 2012Assignee: Argos Therapeutics, Inc.Inventors: Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
-
Patent number: 8124089Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: June 11, 2009Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120045816Abstract: Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human animal sources fed a diet supplemented with Neu5Gc competitor. Also provided herein are methods of treating a human subject with said compositions.Type: ApplicationFiled: July 14, 2011Publication date: February 23, 2012Inventors: Darius Ghaderi, Ajit Varki
-
Publication number: 20120045394Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini
-
Patent number: 8119771Abstract: Products for altering IL-33 activity including antibodies that specifically bind to an epitope with the polypeptide sequence of IL-33 such as antibodies that specifically bind to a protease cleavage region of IL-33 comprising the amino acid sequence of SEQ ID No. 17, or SEQ ID NO. 16, or SEQ ID NO. 10; isolated IL-33 polypeptide(s); and compositions comprising a soluble IL-33 receptor linked to an enzyme capable of cleaving IL-33 or an antibody that binds to IL-33 linked to an enzyme capable of cleaving IL-33. The invention also relates to methods of altering IL-33 activity using the products described herein.Type: GrantFiled: April 28, 2008Date of Patent: February 21, 2012Assignee: The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near DublinInventor: Seamus J. Martin
-
Patent number: 8119603Abstract: Modified human interferon polypeptides and uses thereof are provided.Type: GrantFiled: January 28, 2005Date of Patent: February 21, 2012Assignee: AMBRX, Inc.Inventors: Ho Sung Cho, Thomas O. Daniel, Anna-Maria Hays, Troy E. Wilson
-
Patent number: 8119786Abstract: Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of making and using said reagents and diagnostic kits.Type: GrantFiled: September 14, 2009Date of Patent: February 21, 2012Assignee: Schering CorporationInventors: Alain Vicari, Janine M. Morales, Joseph Hedrick, Albert Zlotnik
-
Publication number: 20120039989Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
-
Publication number: 20120039843Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).Type: ApplicationFiled: September 8, 2011Publication date: February 16, 2012Applicant: N.V. OrganonInventors: Ebo Sybren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
-
Patent number: 8114395Abstract: This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon.Type: GrantFiled: April 18, 2008Date of Patent: February 14, 2012Assignee: Sichuan Biotechnology Research CenterInventors: Guangwen Wei, Rongbing Guo, Renhuai Zhang
-
Publication number: 20120035344Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: July 29, 2011Publication date: February 9, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling